Dementia with Lewy Bodies (Headway-DLB)

A global, multi-center, randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating intepirdine to address visual hallucinations and behavioral disturbances in subjects with dementia with Lewy bodies (DLB).

The efficacy, safety and tolerability of intepirdine at doses of 70 mg and 35 mg daily are being evaluated over a 24-week treatment period in approximately 240 subjects with DLB. Subjects currently receiving stable background therapy for DLB are allowed to participate in the study. The primary efficacy evaluations are the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC+) and a computerized cognitive battery. Subjects who complete the HEADWAY-DLB study are eligible to receive intepirdine in an extension study.

Compound:
Intepirdine

Therapeutic Area(s):

  • Dementia with Lewy bodies (DLB)

For More Information:
ClinicalTrials.gov